cognoa-logo

Cognoa Launches Pivotal Study of the First Digital Diagnostic for Autism.

Palo Alto, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of pediatric behavioral health, announced today initiation of its Pivotal Study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD). The company anticipates submitting the results of this multi-site, prospective, blinded, active comparator study to the U.S. Food and Drug Administration (FDA)…

cognoa-logo

Cognoa and EVERSANA™ announce partnership to advance the commercialization standard for prescription digital medicines.

PALO ALTO, Calif. and CHICAGO, Sept. 10, 2019 /PRNewswire/ — Cognoa, a company at the forefront of pediatric behavioral health, and EVERSANA™, the leading independent provider of global commercial services to the life science industry, today announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance. By leveraging the existing healthcare infrastructure utilized by pharmaceutical companies…

cognoa-logo

Cognoa Licenses Innovative Digital Therapeutic Technology.

PALO ALTO, Calif., April 10, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has exclusively licensed technology from the Stanford University School of Medicine to accelerate development and worldwide commercialization of a novel digital therapeutic for children with autism spectrum disorder (ASD). Underscoring the need for earlier access to personalized…

cognoa-logo

Cognoa Receives FDA Breakthrough Designations for Autism Diagnostic and Digital Therapeutic Devices.

PALO ALTO, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has received Breakthrough Device designations from the U.S. Food and Drug Administration (FDA) for its lead products, the first digital diagnostic and digital therapeutic devices for autism. These products are the foundation of  Cognoa’s precision health platform…

cognoa-logo

Cognoa Selected by Cambia Health Solutions to Provide Support for Employees Raising Young Children.

Email Print Friendly ShareJanuary 08, 2019 09:03 ET | Source: Cognoa PALO ALTO, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) — Cognoa, a digital behavioral health company, announced today that Cambia Health Solutions, Inc. (Cambia) is incorporating Cognoa’s evidence-based platform within its subsidiary health plans. Cognoa provides support for employees caring for children older than one. Cognoa offers reliable guidance on day-to-day challenges and personalized resources that enable…

logo-jamia

Cognoa Demonstrates Advances of its AI-Based Technology for Identifying Autism in Children

PALO ALTO, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) — Cognoa, a digital behavioral health company, today announces results from a clinical study of its second-generation AI based algorithms which demonstrates accuracy improvements over its first-generation screening algorithm in supporting the diagnosis of autism spectrum disorder (ASD) in young children. Published in Journal of the American Medical Informatics Association, the data provides…

cognoa-logo

SAP Teams with Cognoa to Bridge Gap in Healthcare for Employees Raising Young Children.

PALO ALTO, Calif., June 12, 2018 (GLOBE NEWSWIRE) — Cognoa, a digital behavioral health company, today announces its partnership with SAP, a market leader in enterprise application software. More than 19,000 SAP employees in North America will now have access to Cognoa’s app to help their children reach their full potential – socially, emotionally and developmentally. Cognoa empowers employees with clinically validated…

cognoa-logo

Cognoa Hits Major Milestone Towards First AI-Based Autism Diagnostic.

PALO ALTO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — Cognoa, a company offering an AI-based platform for pediatric behavioral health diagnostics and digital therapeutics, announces that the U.S. Food and Drug Administration (FDA) has established that Cognoa’s software is a Class II diagnostic medical device for autism. This milestone will expand Cognoa’s ability to offer its solution to enterprise customers,…

cognoa-logo

Cognoa Hires Vice President of Medical, Further Advancing Developmental Diagnosis Technology.

PALO ALTO, CA–(Marketwired – Jun 14, 2017) – Cognoa, a digital health company revolutionizing how children with developmental delays are diagnosed and supported, today announces Sharief Taraman, MD as its vice president of medical and clinical. Dr. Taraman will lead the company’s further clinical validation of Cognoa’s child development software for payers and employers as well as the company’s U.S. Food…

Location

Social